Abstract: An object of the present invention is to provide a drug which prevents progress of Alzheimer's disease and a method of preventing progress of Alzheimer's disease. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy and is useful as an agent for preventing or treating brain atrophy. Brain atrophy observed in aging or neurodegenerative diseases can be prevented or treated by administering 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.

Abstract: One or more processors calculate a first score value indicating likelihood of being a type of the identification target drug with respect to each of a plurality of types of drugs from the image by using a first trained model trained to identify a type of an identification target drug from an image obtained by capturing the identification target drug, identify one or more appearance attributes of the identification target drug from the image, acquire information on drug types matching the attributes of the identification target drug from the drug master file including information on one or more appearance attributes regarding each of a plurality of types of drugs identifiable by the first trained model, calculate a second score value by using the first score value and a value being set for the attribute; and present a candidate for the type of the identification target drug based on second score value.

Abstract: An imaging assisting apparatus includes: a first member in which a packaging bag containing a drug is placed, and has a first surface disposed on a side opposite to a surface to be imaged of the packaging bag; a second member which extends from the first member toward a side opposite to the first surface where the packaging bag is placed, and is configured to suppress incidence of environmental light on the packaging bag placed in the first member; and a third member which extends from the first member toward the side opposite to the first surface where the packaging bag is placed, and is disposed on a side opposite to the second member across the first member.

Abstract: A pharmaceutical composition comprising Components (1) and (2): (1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and (2) a compound having a partial structure containing two heteroatoms separated by at least two carbon atoms, or a sulfite thereof.

Abstract: A pharmaceutical composition comprising Components (1) and (2): (1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and (2) a specific amine.

Abstract: A medicine verification device of the present invention includes: a detection unit that detects a boundary recess formed at a boundary position between a plurality of packaging bags each of which packs a medicine and is connected to form a continuous packaging bag having a strip-like shape; and an image capturing unit that captures an image of a surface of an imaging target portion on which at least the boundary recess is located a plurality of times while imaging conditions are changed in a state where light is emitted toward the surface of the imaging target portion in the continuous packaging bag, wherein the detection unit detects the boundary recess in the imaging target portion on the basis of the plurality of images captured while changing the imaging conditions by the image capturing unit.

Abstract: A region of a drug to be identified is detected from a captured image generated by imaging the drug to be identified that is imparted with engraved mark and/or print. The region of the drug to be identified in the captured image is processed to acquire an engraved mark and print extraction image that is an extracted image of the engraved mark and/or print of the drug to be identified. The engraved mark and print extraction image is input, and a drug type of the drug to be identified is inferred to acquire a candidate of the drug type of the drug to be identified.

Abstract: Provided are a drug and a method which suppress progress of tauopathy such as Alzheimer's disease. 1-(3-(2-(1-B enzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of phosphorylated tau protein and an effect of reducing the amount of amyloid ? protein in the brain parenchyma, and thus is effective as an agent for preventing or treating tauopathy. Tauopathy can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.

Abstract: An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer’s disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid ? protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid ? protein in the brain. Disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer’s disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.

Abstract: There is provided a medicine management system capable of checking a receipt status and a dosage stage of delivered medicines even at a delivery source. The medicine management system includes a management server for managing a receipt status and a dosage status of medicines to be delivered, a first terminal having a function of notifying the management server of information indicating receipt of medicines when the medicines have been received, a second terminal having a function of notifying the management server of information indicating dosage of medicines when the medicines have been taken, and a third terminal having a function of acquiring from the management server and displaying information on a receipt status and a dosage status of medicines.

Abstract: An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.

Abstract: A drug list display method includes: obtaining a first image of drugs captured from one side of the drugs; clipping from the first image, areas where the respective drugs are displayed to obtain first clipped images; displaying the first clipped images in a list form in a certain order in a first area on a display in such a manner that one or more of the first clipped images may be designated; determining correct drugs for first clipped images designated by a user; and displaying information on the correct drugs determined for the respective first clipped images in a second area on the display different from the first area, wherein the first clipped images and the corresponding information on the correct drugs are displayed in association with each other.

Abstract: The present invention addresses the problem of providing a therapeutic agent for RNA viral infection that includes a novel combination of a pyrazine derivative and a specific compound, the novel combination exhibiting an effect against the RNA virus. The present invention also addresses the problem of providing a therapeutic agent for RNA viral infection that includes a combination of a pyrazine derivative and a specific compound, the combination being capable of simultaneously enhancing anti-virus activities against multiple RNA viruses. The present invention provides a therapeutic agent for RNA viral infection obtained by combining a pyrazine derivative or a salt thereof and a thiopurine derivative.

Abstract: This method for producing a freeze-dried formulation including an amorphous form of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt is useful as a method for producing a freeze-dried formulation having uniform quality.

Abstract: An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid ? protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid ? protein in the brain. Disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.

Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.

Abstract: A drug inspection apparatus inspects drugs that are prepared based on prescription information and are packaged in a prescription bag. A drug database includes drug images of drugs that can be prepared. A comparison target selection section acquires drug images of drugs, which are prepared according to the prescription, and drugs similar thereto from the drug database. A first drug determination section compares captured images of prepared drugs with the drug images acquired from the drug database, and determines drugs present in the captured images and the number thereof. An inspection result determination section determines whether or not the prepared drugs and the number thereof match the prescription information based on the prescription information.

Abstract: Coronavirus infection can be treated by administering a pharmaceutical composition comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to coronavirus infection patient with non-serious pneumonia.

Abstract: An object of the present invention is to provide a dispensing audit support apparatus and a dispensing audit support method with a high collation accuracy robustness. According to a dispensing audit support apparatus according to one aspect of the present invention, since a position, shape and size of a region of interest are set according to a position of a collation-target medicine in a captured image, and a position, shape and size of a master image are set according to the set region of interest, it is possible to avoid or reduce distortion of the medicine shape, blur, inclusion of an end part into the image, and the like due to the position and orientation of the collation-target medicine. Therefore, influence on collation accuracy is small, and it is possible to enhance the robustness of the collation accuracy.

Abstract: Provided are a drug recognizing apparatus, a drug recognizing method, and a drug recognizing program capable of enhancing robustness of a master image in a case where a drug is recognized. The drug recognizing apparatus includes an illumination unit that illuminates a drug; an imaging unit that images the illuminated drug; a storage unit that stores a master image for each drug type; a drug position acquiring unit that acquires a position of the drug on the basis of a captured image obtained by the imaging unit; a master image generating unit that generates the master image from a drug area in the captured image; an updating determination unit that determines whether to update the master image on the basis of the position of the drug acquired by the drug position acquiring unit; and a registration unit that registers the master image in the storage unit in a case where it is determined that the master image is to be updated.